Gsk Share Discussion Threads

[montyhedge] 03/9/2020 21:56

Don't forget each year the Coronavirus vaccine has to be given just like the flu jab, then the money rolls in.

[spud] 03/9/2020 18:17

I'd estimate a first to Market could pop the price by 10-15%. What happens in the weeks following is anyone's guess although I suspect we'll see a steady decline negating that rise. spud

[ianood] 03/9/2020 18:11

EI - Agreed re non profit basis, however, there will be a massive Kudos factor for the first (non Russian!!) to market.

[essentialinvestor] 03/9/2020 17:32

GSK have clearly stated their COVID vaccine will be supplied on a non profit basis.

Yes they can offset development costs in their pricing, but to think this would

be some sort of goldmine is la la land stuff.

GSK have huge contracts with numerous governments for a range of their existing vaccinations. They very last outcome they want is to be accused of profiteering from a gloval pandemic.

Arguably of far more significance is getting this outbreak under control so
take up rstes on their existing suite of vaccines returns to pre COVID levels.

[geckotheglorious] 03/9/2020 14:56

Pfizer (PFE -0.3%) CEO Albert Bourla confirms that results from its large-scale late-stage study of COVID-19 vaccine candidate BNT162b2 will be available next month. If positive, it will immediately file for emergency use authorization in the U.S.

As of yesterday, 23K people have been enrolled in the 30K-subject trial.

[geckotheglorious] 03/9/2020 11:18

Agreed Spud.

World population - 7.6billion

Confirmed cases - 26,037,404
Recovered cases - 17,294,713
Deaths - 863,119

Long long way to go perhaps....

Who's to know.

[spud] 03/9/2020 11:10

I didn't word it very well did I! I meant to say enough individuals who had not already been infected. spud

[alphorn] 03/9/2020 11:00

How would you know that any new vaccine candidate is efficace and safe if it was not given to healthy individuals to determine whether they develop the illness or not?

[spud] 03/9/2020 10:53

Indeed. As my partner says, the most difficult part is getting enough patients with the virus to test. They'll probably have to infect healthy volunteers in order to get the required numbers. spud

[geckotheglorious] 03/9/2020 10:48

How on earth will Sanofi/GSK be first???

They're doing Phase 1/2

AstraZeneca/Oxford are doing Phase 3 now.
Phase 3 started 28th June, in Brazil.

Final Phase 3 trials in US.(Enrolement open – 30,000 adults from different racial/ethnic groups) 10,000 get salty water, 20,000 get vacine, two doses, 4 weeks apart.

Ridiculous claim

[montyhedge] 03/9/2020 09:56

I feel Sanofi/GSK have more experience on vaccines, they are also working around the clock.

[spud] 03/9/2020 09:51

I'm not so sure Monty. My partner works for AZN and has been working non stop in the lab during lockdown. We shall see. spud

[montyhedge] 03/9/2020 09:48

I reckon Sanofi/GSK will be first.Then a great boost in shareprice, must be new highs into the 2000p +.

[spud] 03/9/2020 08:23

Sanofi, GlaxoSmithKline Start Phase 1/2 Trial of Covid-19 Vaccine CandidateSource: Dow Jones NewsBy Pietro Lombardi Sanofi SA and GlaxoSmithKline PLC are enrolling more than 400 people to start the Phase 1/2 clinical trial of their Covid-19 vaccine candidate, with a goal of moving to Phase 3 by the end of the year and requesting regulatory approval in the first half of next year.The French pharmaceutical major said Thursday that the companies are targeting the production of up to a billion doses next year.Preclinical studies were promising, it said.The Phase 1/2 trial is a randomized, double blind and placebo-controlled trial which will evaluate the safety, tolerability and immune response of the Covid-19 vaccine candidate. First results are expected in early December, which would allow the companies to kick off a Phase 3 trial in December.For the current trials, 440 people are being enrolled.The U.S. Department of Health and Human Services is supporting the development of the vaccine, including with funding.spud

[ayl30] 03/9/2020 07:34

Today's rns is good news, great to see GSK active there is a big and global market waiting for product

[toffeeman] 02/9/2020 21:32

There are much more recent papers:

hxxps://care.diabetesjournals.org/content/early/2020/07/03/dc20-0229


I always get a flu jab

[toffeeman] 02/9/2020 21:24

I would think that research published in 2015 would have have more of an impact if it were seen as important.

[essentialinvestor] 02/9/2020 19:19

From this year:

[toffeeman] 02/9/2020 18:51

EI - where is that research please?

[essentialinvestor] 02/9/2020 17:11

For anyone a little bit older or in a higher risk group,

the flu jab may be worth considering this year, even if you usually skip it.

There is also some data that having the vaccine early reduces both stroke and

heart attack risk over the next 12 months. Researchers can't determine the reason

for this.

[montyhedge] 02/9/2020 16:58

GSK relative strength top 25%.https://www.nasdaq.com/articles/relative-strength-alert-for-glaxosmithkline-2020-09-01

[essentialinvestor] 02/9/2020 16:50

monty, the main issue for GSK is Not necessarily developing a vaccine,

as COVID is impacting their wider vaccination business with lower uptake levels,

any successful vaccine will do. If Oxford/Astra are first that really does not matter.

GSK spell out in the last Q updste the impact on the business from COVID.

[geckotheglorious] 02/9/2020 16:44

So that's why they don't want HCQ+Zpac+Zinc to be shown to be highly efficacious...
All about money.